Travere Therapeutics (TVTX) EBITDA (2011 - 2026)

Travere Therapeutics has reported EBITDA for 16 years, with the latest figure at -$37.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 11.94% year-over-year to -$37.0 million; the trailing twelve-month figure through Mar 2026 stood at -$21.6 million (up 90.41% YoY), and the FY2025 full-year result was -$26.7 million, up 91.67% from the prior year.
• EBITDA for Q1 2026 stood at -$37.0 million, down from $2.6 million in the prior quarter.
• The five-year high for EBITDA was $150.9 million in Q3 2023, with the low at -$136.5 million in Q1 2024.
• Historically, EBITDA has averaged -$45.6 million across 5 years, with a median of -$66.4 million in 2022.
• Annual changes were most pronounced in 2023 — EBITDA surged 321.09% — and 2024, when it plunged 135.9%.
• Travere Therapeutics' EBITDA stood at -$69.0 million in 2022, then fell by 27.44% to -$88.0 million in 2023, then soared by 32.56% to -$59.3 million in 2024, then jumped by 104.37% to $2.6 million in 2025, then tumbled by 1525.4% to -$37.0 million in 2026.
• The last three EBITDA figures came in at -$37.0 million (Q1 2026), $2.6 million (Q4 2025), and $25.5 million (Q3 2025), per Business Quant data.